Recent progress on computer-aided inhibitor design of H5N1 influenza a virus

Current Computer-Aided Drug Design

Volumn 6, Issue 2, 2010, Pages 139-146

  Guo, Xiaoli ^a   Wang, Jing Fang ^a   Zhu, Yisheng ^a   Wei, Dong Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Adamantanes; Drug resistance; H5n1 viruses; M2 ion channel inhibitors; NA inhibitors; Oseltamivir; Structure based drug design

Indexed keywords

COMPUTATIONAL CHEMISTRY; DRUG THERAPY; VIRUSES;

ADAMANTANES; COMPUTER-AIDED; DRUG-RESISTANCE; H5N1 VIRUS; ION-CHANNEL INHIBITORS; M2-ION CHANNEL INHIBITOR; NA INHIBITOR; OSELTAMIVIR; RECENT PROGRESS; STRUCTURE BASED DRUG DESIGNS;

MOLECULAR DYNAMICS;

ADAMANTANE DERIVATIVE; AMANTADINE; ANTIVIRUS AGENT; LYSOVIR; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ARTICLE; AVIAN INFLUENZA; BIOINFORMATICS; CLINICAL TRIAL; COMPUTER AIDED DESIGN; COMPUTER MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLUENZA; INFLUENZA VIRUS A H5N1; MOLECULAR DYNAMICS; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; INFLUENZA A VIRUS (H5N1);

ANIMALS; ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; OSELTAMIVIR;

EID: 77953670137     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340910791202487     Document Type: Article

References (74)

1. Fauci, A.S. Pandemic influenza threat and preparedness. Emerg. Infect. Dis., 2006, 12, 73-77.
2. Subbarao, K.; Klimov, A.; Katz, J.; Regnery, H.; Lim, W.; Hall, H.; Perdue, M.; Swayne, D.; Bender, C.; Huang, J.; Hemphill, M.; Rowe, T.; Shaw, M.; Xu, X.; Fukuda, K.; Cox, N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science, 1998, 279, 393-396.
3. Guan, Y.; Poon, L.L.; Cheung, C.Y.; Ellis, T.M.; Lim, W.; Lipatov, A.S.; Chan, K.H.; Sturm-Ramirez, K.M.; Cheung, C.L.; Leung, Y.H.; Yuen, K.Y.; Webster, R.G.; Peiris, J.S. H5N1 influenza: a protean pandemic threat. Proc. Natl. Acad. Sci. USA, 2004, 101, 8156-8161.
4. Longini, I.M., Jr.; Nizam, A.; Xu, S.; Ungchusak, K.; Hanshaoworakul, W.; Cummings, D.A.; Halloran, M.E. Containing pandemic influenza at the source. Science, 2005, 309, 1083-1087.
5. Webster, R.G.; Peiris, M.; Chen, H.; Guan, Y. H5N1 outbreaks and enzootic influenza. Emerg. Infect. Dis., 2006, 12, 3-8.
6. Ungchusak, K.; Auewarakul, P.; Dowell, S.F.; Kitphati, R.; Auwanit, W.; Puthavathana, P.; Uiprasertkul, M.; Boonnak, K.; Pittayawonganon, C.; Cox, N.J.; Zaki, S.R.; Thawatsupha, P.; Chittaganpitch, M.; Khontong, R.; Simmerman, J.M.; Chunsutthiwat, S. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med., 2005, 352, 333-340.
7. Kandun, I.N.; Wibisono, H.; Sedyaningsih, E.R.; Yusharmen; Hadisoedarsuno, W.; Purba, W.; Santoso, H.; Septiawati, C.; Tresnaningsih, E.; Heriyanto, B.; Yuwono, D.; Harun, S.; Soeroso, S.; Giriputra, S.; Blair, P.J.; Jeremijenko, A.; Kosasih, H.; Putnam, S.D.; Samaan, G.; Silitonga, M.; Chan, K.H.; Poon, L.L.; Lim, W.; Klimov, A.; Lindstrom, S.; Guan, Y.; Donis, R.; Katz, J.; Cox, N.; Peiris, M.; Uyeki, T.M. Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med., 2006, 355, 2186-2194.
8. Wang, H.; Feng, Z.; Shu, Y.; Yu, H.; Zhou, L.; Zu, R.; Huai, Y.; Dong, J.; Bao, C.; Wen, L.; Wang, H.; Yang, P.; Zhao, W.; Dong, L.; Zhou, M.; Liao, Q.; Yang, H.; Wang, M.; Lu, X.; Shi, Z.; Wang, W.; Gu, L.; Zhu, F.; Li, Q.; Yin, W.; Yang, W.; Li, D.; Uyeki, T.M.; Wang, Y. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet, 2008, 371, 1427-1434.
9. Nguyen, T.H.; Farrar, J.; Horby, P. Person-to-person transmission of influenza A (H5N1). Lancet, 2008, 371, 1392-1394.
10. Dawood, F.S.; Jain, S.; Finelli, L.; Shaw, M.W.; Lindstrom, S.; Garten, R.J.; Gubareva, L.V.; Xu, X.; Bridges, C.B.; Uyeki, T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med., 2009, 360, 2605-2615.
11. Neumann, G.; Noda, T.; Kawaoka, Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature, 2009, 459, 931-939.
12. Naffakh, N.; van der Werf, S. April 2009: an outbreak of swine-origin influenza A(H1N1) virus with evidence for human-to-human transmission. Microbes. Infect., 2009, 11, 725-728.
13. Boelle, P.Y.; Bernillon, P.; Desenclos, J.C. A preliminary estimation of the reproduction ratio for new influenza A(H1N1) from the outbreak in Mexico, March-April 2009. Eur. Surveill., 2009, 14, 19205.
14. Fraser, C.; Donnelly, C.A.; Cauchemez, S.; Hanage, W.P.; Van Kerkhove, M.D.; Hollingsworth, T.D.; Griffin, J.; Baggaley, R.F.; Jenkins, H.E.; Lyons, E.J.; Jombart, T.; Hinsley, W.R.; Grassly, N.C.; Balloux, F.; Ghani, A.C.; Ferguson, N.M.; Rambaut, A.; Pybus, O.G.; Lopez-Gatell, H.; Alpuche-Aranda, C.M.; Chapela, I.B.; Zavala, E.P.; Guevara, D.M.; Checchi, F.; Garcia, E.; Hugonnet, S.; Roth, C. Pandemic potential of a strain of influenza A (H1N1): early findings. Science, 2009, 324, 1557-1561.
15. Maines, T.R.; Jayaraman, A.; Belser, J.A.; Wadford, D.A.; Pappas, C.; Zeng, H.; Gustin, K.M.; Pearce, M.B.; Viswanathan, K.; Shriver, Z.H.; Raman, R.; Cox, N.J.; Sasisekharan, R.; Katz, J.M.; Tumpey, T.M. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science, 2009, 325, 484-487.
16. Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med., 2005, 353, 1363-1373.
17. Monto, A.S. Vaccines and antiviral drugs in pandemic preparedness. Emerg. Infect. Dis., 2006, 12, 55-60.
18. Landa, S.; Machacek, V. Sur l'adamantane, nouvel hydrocarbure extrait du naphe. Coll. Czech. Chem. Commun., 1933, 5, 1-5.
19. Prelog, V.; Seiwerth, R. Uber eine neue, ergiebigere Darstellung des Adamantans. Chem. Res., 1941, 74, 1769-1772.
20. Pinto, L.H.; Holsinger, L.J.; Lamb, R.A. Influenza virus M2 protein has ion channel activity. Cell, 1992, 69, 517-528.
21. Hay, A.J.; Wolstenholme, A.J.; Skehel, J.J.; Smith, M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J., 1985, 4, 3021-3024.
22. Hayden, F.G. Antiviral resistance in influenza viruses--implications for management and pandemic response. N. Engl. J. Med., 2006, 354, 785-788.
23. Cheung, C.L.; Rayner, J.M.; Smith, G.J.; Wang, P.; Naipospos, T.S.; Zhang, J.; Yuen, K.Y.; Webster, R.G.; Peiris, J.S.; Guan, Y.; Chen, H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis., 2006, 193, 1626-1629.
24. Weinstock, D.M.; Zuccotti, G. Adamantane resistance in influenza JAMA, 2006, 295, 934-936.
25. He, G.; Qiao, J.; Dong, C.; He, C.; Zhao, L.; Tian, Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China. Antiviral. Res., 2008, 77, 72-76.
26. Buranathai, C.; Amonsin, A.; Chaisigh, A.; Theamboonlers, A.; Pariyothorn, N.; Poovorawan, Y. Surveillance activities and molecular analysis of H5N1 highly pathogenic avian influenza viruses from Thailand, 2004-2005. Avian. Dis., 2007, 51(1 Suppl), 194-200.
27. Schunemann, H.J.; Hill, S.R.; Kakad, M.; Bellamy, R.; Uyeki, T.M.; Hayden, F.G.; Yazdanpanah, Y.; Beigel, J.; Chotpitayasunondh, T.; Del Mar, C.; Farrar, J.; Tran, T.H.; Ozbay, B.; Sugaya, N.; Fukuda, K.; Shindo, N.; Stockman, L.; Vist, G.E.; Croisier, A.; Nagjdaliyev, A.; Roth, C.; Thomson, G.; Zucker, H.; Oxman, A.D. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet. Infect. Dis., 2007, 7, 21-31.
28. Peiris, J.S.; Yu, W.C.; Leung, C.W.; Cheung, C.Y.; Ng, W.F.; Nicholls, J.M.; Ng, T.K.; Chan, K.H.; Lai, S.T.; Lim, W.L.; Yuen, K.Y.; Guan, Y. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet, 2004, 363, 617-619.
29. Schnell, J.R.; Chou, J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature, 2008, 451, 591-595.
30. Stouffer, A.L.; Acharya, R.; Salom, D.; Levine, A.S.; Di Costanzo, L.; Soto, C.S.; Tereshko, V.; Nanda, V.; Stayrook, S.; DeGrado, W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature, 2008, 451, 596-599.
31. Jing, X.; Ma, C.; Ohigashi, Y.; Oliveira, F.A.; Jardetzky, T.S.; Pinto, L.H.; Lamb, R.A. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. USA, 2008, 105, 10967-10972.
32. Khurana, E.; Dal Peraro, M.; DeVane, R.; Vemparala, S.; DeGrado, W.F.; Klein, M.L. Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus. Proc. Natl. Acad. Sci. USA, 2009, 106, 1069-1074.
33. von Itzstein, M.; Wu, W.Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Van Phan, T.; Smythe, M.L.; White, H.F.; Oliver, S.W.; et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363, 418-423.
34. Hurt, A.C.; Ho, H.T.; Barr, I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert. Rev. Anti. Infect. Ther., 2006, 4, 795-805.
35. Gubareva, L.V.; Matrosovich, M.N.; Brenner, M.K.; Bethell, R.C.; Webster, R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis., 1998, 175, 1257-1262.
36. de Jong, M.D.; Tran, T.T.; Truong, H.K.; Vo, M.H.; Smith, G.J.; Nguyen, V.C.; Bach, V.C.; Phan, T.Q.; Do, Q.H.; Guan, Y.; Peiris, J.S.; Tran, T.H.; Farrar, J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med., 2005, 353, 2667-2672.
37. Gubareva, L.V.; Webster, R.G.; Hayden, F.G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother., 2001, 45, 3403-3408.
38. McKimm-Breschkin, J.L. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat. Respir. Med., 2005, 4, 107-116.
39. Mishin, V.P.; Hayden, F.G.; Gubareva, L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother, 2005, 49, 4515-4520.
40. Nimmanpipug, P.; Jitonnom, J.; Ngaojampa, C.; Hannongbua, S.; Lee, V.S. A computational H5N1 neuraminidase model and its binding to commercial drugs. Mol. Simul., 2007, 33, 487-493.
41. Calfee, D.P.; Peng, A.W.; Cass, L.M.; Lobo, M.; Hayden, F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother., 1999, 43, 1616-1620.
42. Honda, T.; Masuda, T.; Yoshida, S.; Arai, M.; Kaneko, S.; Yamashita, M. Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir. Bioorg. Med. Chem. Lett., 2002, 12, 1925-1928.
43. Masuda, T.; Shibuya, S.; Arai, M.; Yoshida, S.; Tomozawa, T.; Ohno, A.; Yamashita, M.; Honda, T. Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir. Bioorg. Med. Chem. Lett., 2003, 13, 669-673.
44. Macdonald, S.J.; Watson, K.G.; Cameron, R.; Chalmers, D.K.; Demaine, D.A.; Fenton, R.J.; Gower, D.; Hamblin, J.N.; Hamilton, S.; Hart, G.J.; Inglis, G.G.; Jin, B.; Jones, H.T.; McConnell, D.B.; Mason, A.M.; Nguyen, V.; Owens, I.J.; Parry, N.; Reece, P.A.; Shanahan, S.E.; Smith, D.; Wu, W.Y.; Tucker, S.P. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother., 2004, 48, 4542-4549.
45. Macdonald, S.J.; Cameron, R.; Demaine, D.A.; Fenton, R.J.; Foster, G.; Gower, D.; Hamblin, J.N.; Hamilton, S.; Hart, G.J.; Hill, A.P.; Inglis, G.G.; Jin, B.; Jones, H.T.; McConnell, D.B.; McKimm-Breschkin, J.; Mills, G.; Nguyen, V.; Owens, I.J.; Parry, N.; Shanahan, S.E.; Smith, D.; Watson, K.G.; Wu, W.Y.; Tucker, S.P. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem., 2005, 48, 2964-2971.
46. Kim, C.U.; Lew, W.; Williams, M.A.; Wu, H.; Zhang, L.; Chen, X.; Escarpe, P.A.; Mendel, D.B.; Laver, W.G.; Stevens, R.C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem., 1998, 41, 2451-2460.
47. Rameix-Welti, M.A.; van der Werf, S.; Naffakh, N. Sensitivity of H5N1 influenza viruses to oseltamivir: an update. Future Virol., 3, 157-165.
48. de Jong, M.D.; Bach, V.C.; Phan, T.Q.; Vo, M.H.; Tran, T.T.; Nguyen, B.H.; Beld, M.; Le, T.P.; Truong, H.K.; Nguyen, V.V.; Tran, T.H.; Do, Q.H.; Farrar, J. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med., 2005, 352, 686-691.
49. Le, Q.M.; Kiso, M.; Someya, K.; Sakai, Y.T.; Nguyen, T.H.; Nguyen, K.H.; Pham, N.D.; Ngyen, H.H.; Yamada, S.; Muramoto, Y.; Horimoto, T.; Takada, A.; Goto, H.; Suzuki, T.; Suzuki, Y.; Kawaoka, Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature, 2005, 437, 1108.
50. Beigel, J.H.; Farrar, J.; Han, A.M.; Hayden, F.G.; Hyer, R.; de Jong, M.D.; Lochindarat, S.; Nguyen, T.K.; Nguyen, T.H.; Tran, T.H.; Nicoll, A.; Touch, S.; Yuen, K.Y. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med., 2005, 353, 1374-1385.
51. Saad, M.D.; Boynton, B.R.; Earhart, K.C.; Mansour, M.M.; Niman, H.L.; Elsayed, N.M.; Nayel, A.I.; Abdelghani, A.S.; Essmat, H.M.; Labib, E.M.; Ayoub, E.A.; Monteville, M.R. Detection of Oseltamivir Resistance Mutation N294S in Humans with Influenza A H5N1. Options for the Control of Influenza VI Conference, Toronto, Canada, 2007.
52. Wei, D.Q.; Du, Q.S.; Sun, H.; Chou, K.C. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem. Biophys. Res. Commun., 2006, 344, 1048-1055.
53. Russell, R.J.; Haire, L.F.; Stevens, D.J.; Collins, P.J.; Lin, Y.P.; Blackburn, G.M.; Hay, A.J.; Gamblin, S.J.; Skehel, J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature, 2006, 443, 45-49.
54. Amaro, R.E.; Minh, D.D.; Cheng, L.S.; Lindstrom, W.M., Jr.; Olson, A.J.; Lin, J.H.; Li, W.W.; McCammon, J.A. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J. Am. Chem. Soc., 2007, 129, 7764-7765.
55. Du, Q.S.; Wang, S.Q.; Chou, K.C. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem. Biophys. Res. Commun., 2007, 362, 525-531.
56. Wang, S.Q.; Du, Q.S.; Chou, K.C. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem. Biophys. Res. Commun., 2007, 354, 634-640.
57. Mitrasinovic, P.M. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys. Chem., 2009, 140, 35-38.
58. Gong, K.; Li, L.; Wang, J.F.; Cheng, F.; Wei, D.Q.; Chou, K.C. Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design. Med. Chem., 2009, 5, 242-249.
59. Rungrotmongkol, T.; Frecer, V.; De-Eknamkul, W.; Hannongbua, S.; Miertus, S. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral. Res., 82, 51-58.
60. Mihajlovic, M.L.; Mitrasinovic, P.M. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys. Chem., 2008, 136, 152-158.
61. Collins, P.J.; Haire, L.F.; Lin, Y.P.; Liu, J.; Russell, R.J.; Walker, P.A.; Skehel, J.J.; Martin, S.R.; Hay, A.J.; Gamblin, S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature, 2008, 453, 1258-1261.
62. Garcia-Sosa, A.T.; Sild, S.; Maran, U. Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. J. Chem. Inf. Model., 2008, 48, 2074-2080.
63. Babu, Y.S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T.H.; Hutchison, T.L.; Elliott, A.J.; Parker, C.D.; Ananth, S.L.; Horn, L.L.; Laver, G.W.; Montgomery, J.A. BCX- 1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem., 2000, 43, 3482-3486.
64. Govorkova, E.A.; Leneva, I.A.; Goloubeva, O.G.; Bush, K.; Webster, R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother., 2001, 45, 2723-2732.
65. Sweet, C.; Jakeman, K.J.; Bush, K.; Wagaman, P.C.; McKown, L.A.; Streeter, A.J.; Desai-Krieger, D.; Chand, P.; Babu, Y.S. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob. Agents Chemother., 2002, 46, 996-1004.
66. Chand, P.; Bantia, S.; Kotian, P.L.; El-Kattan, Y.; Lin, T.H.; Babu, Y.S. Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo. Bioorg. Med. Chem., 2005, 13, 4071-4077.
67. Boltz, D.A.; Ilyushina, N.A.; Arnold, C.S.; Babu, Y.S.; Webster, R.G.; Govorkova, E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral. Res., 2008, 80, 150-157.
68. Weis, W.; Brown, J.H.; Cusack, S.; Paulson, J.C.; Skehel, J.J.; Wiley, D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature, 1988, 333, 426-431.
69. Wiley, D.C.; Skehel, J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem., 1987, 56, 365-394.
70. Hoffman, L.R.; Kuntz, I.D.; White, J.M. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J. Virol., 1997, 71, 8808-8820.
71. Bodian, D.L.; Yamasaki, R.B.; Buswell, R.L.; Stearns, J.F.; White, J.M.; Kuntz, I.D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry, 1993, 32, 2967-2978.
72. Yu, K.L.; Torri, A.F.; Luo, G.; Cianci, C.; Grant-Young, K.; Danetz, S.; Tiley, L.; Krystal, M.; Meanwell, N.A. Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorg. Med. Chem. Lett., 2002, 12, 3379-3382.
73. Russell, R.J.; Kerry, P.S.; Stevens, D.J.; Steinhauer, D.A.; Martin, S.R.; Gamblin, S.J.; Skehel, J.J. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc. Natl. Acad. Sci. USA, 2008, 105, 17736-17741.
74. Guo, X.L.; Li, L.; Wei, D.Q.; Zhu, Y.S.; Chou, K.C. Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin. Amino Acids, 2008, 35, 375-382.